ToC+MU+Analysis

include component="page" wikiName="siframework" page="TOC Header" =Transitions of Care Initiative Analysis of Proposed Meaningful Use Stage 2 Requirements=

Announcements

 * ** The Transitions of Care Community has reached consensus on recommendations to the HL7 SDWG for the Consolidated CDA ballot. ** To view work completed as part of the analysis, please reference the materials below.

Purpose of the MU2 NPRM Analysis
In the interest of streamlining adoption, the ToC IG SWG pursued an analysis of the proposed MU2 requirements to perform due diligence and identify issues that adopters will likely have in pursing the proposed MU2 objectives while following the current Consolidated CDA Implementation Guide.

**ToC MU2 Analysis Objectives:**
 * Identify any gaps between the Consolidated CDA standard specification and the proposed Meaningful Use Stage 2 requirements.
 * Identify gaps between the clinical needs previously defined by the ToC participants and the proposed Meaningful Use Stage 2 requirements for care transitions.

**Analysis of Proposed MU2 Requirements:**
 * 1) Clinical Summary (Summary of Care Record- Ambulatory Setting Only)
 * 2) View, Download, or Transmit to 3rd Party (to Patient)
 * 3) Transition of Care (Summary of Care Record)

Consensus on ToC Recommendations to the HL7 SDWG
The ToC IG SWG has reached consensus on recommendations resulting from the analysis for consideration by the HL7 Structured Documents Workgroup for balloting of the HL7 Consolidated CDA Standard. While the majority of the concerns related to adopter understanding of CDA best practices (which will be addressed by the MU2-focused ToC Consolidated CDA Companion Guide), participants identified a few discrepancies that would best be addressed through adjustment of the standard itself. Consensus was achieved in a public forum during the S&I Framework April F2F meeting. Meeting minutes and materials may be accessed through the ToC Initiative F2F Meeting Details page.The consensus recommendations may be downloaded from the **Analysis Artifacts** table below.

Analysis Artifacts

 * < ** Name of the Artifact ** ||< **Description of the Artifact** ||< **Status** ||
 * [[file:siframework/ToC_Recommendations_SDWG_v2.1.docx|ToC Recommendations to HL7 SDWG]] || This document captures analysis findings for recommendation to the HL7 SDWG for the out-of-cycle ballot of the Consolidated CDA standard. The ToC community reached consensus on the recommendations on April 13, 2012 during the S&I Framework F2F meeting. || Completed on April 17, 2012 ||
 * [[file:siframework/ToC_MU_Analysis_v11.xlsx|ToC Analysis Worksheet]] || The ToC Analysis Worksheet is a compilation of several analyses performed by the ToC Implementation Guidance Sub-Workgroup during their development of the ToC Companion Guide. Includes detailed MU requirements and comments. || Completed on April 9, 2012 ||
 * [[file:siframework/ToC_Recommendations_MU2_v1.2.docx|ToC Analysis Recommendations]] || Document containing a summary of the ToC Analysis Recommendations and explanations discussed during the S&I Framework April F2F meeting. The document contains all recommendations as opposed to the ToC Recommendations to HL7 SDWG, which contains recommendations only for the standard. || Completed on April 9, 2012 ||

**Analysis Work Products**
 * = **Name of Contribution Artifact** ||= **Owners** ||= **Organization(s)** ||= **Description** ||= **Last Updated** ||
 * [[file:CCDA_MU2_mapping_V18.xls]] || David Tao || Siemens || Version 18 corrected some section numbers to correspond with latest C-CDA (May 2012 ballot version). || May 11, 2012 ||
 * [[file:siframework/MUSCR.xlsx|MU2 Analysis]] || Keith W. Boone || GE Healthcare || Detailed MU2 NPRM requirements and maps them to CCDA content. Further details and explanations may be found in [|Keith Boone's blog]. || March 14, 2012 ||
 * [[file:siframework/TOC_CCDA_Requirements_Analysis_v10.xls|TOC CCDA Requirements Analysis, Version 10]] || Holly Miller, MD; Russell Leftwich, MD; David Tao || MedAllies, Inc.; State of Tennessee; Siemens || Detailed ToC exchange requirements and comments on CCDA. || March 30, 2012 ||

Analysis Resources

 * < **Name of the Resource** ||< **Description of the Resource** ||< **Source** ||
 * [|Meaningful Use - The Whiteboard Story] || __//Meaningful Use - The Whiteboard Story//__ details Meaningful Use Stage 1 objectives in comparison to the proposed Meaningful Use Stage 2 objectives. || [|The Advisory Board Company] ||
 * [|MU2 NPRM] || The CMS NPRM published in the Federal Register on March 7, 2012 || Federal Register ||
 * [[file:siframework/Standards&CertificationMU2.pdf|2014 Standards & Certification Proposed Rule]] || The ONC NPRM containing the required standards for the MU2 objectives. || HHS ||
 * [[file:siframework/Transitions of Care_CEDD_Version 2.0_March 2012.docx|Transitions of Care CEDD March, 2012]] || March release of the ToC CEDD which details the ToC data requirements for care transitions. || ToC CEDD Wiki Page ||
 * [|Consolidated CDA DSTU Download] || Link to the HL7 SDWG where the Consolidated CDA IG - Draft Standard for Trial Use may be downloaded. || [|HL7 SDWG] ||

Contributors to the ToC MU2 Analysis
Contributors of both analysis and artifacts are listed below for reference.
 * **Name** || **Organization** ||
 * David Tao || Siemens ||
 * Keith W. Boone || GE Healthcare ||
 * Russell Leftwich, MD || State of Tennessee ||
 * Holly Miller, MD || MedAllies, Inc. ||
 * Emma Jones || Allscripts ||
 * Gaby Jewell || Cerner ||
 * Calvin Beebe || Mayo Clinic ||

include component="page" wikiName="siframework" page="space.template.inc_contentleft_end"